MAD2L2是卵巢癌的关键调节剂,促进瘤进展
Kejun Xu1, Xiaojiao Zheng1, Hongyan Shi1
1Gynaecology and Obstetrics Department, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, People's Republic of China.
Scientific reports
|January 3, 2024
概括
卵巢癌中Mitotic Arrest Deficient 2 Like 2 (MAD2L2) 过度表达与生存率差相关,并通过影响细胞代谢和免疫反应促进瘤进展,提供新的治疗点.
科学领域:
- 妇科瘤学 妇科瘤学
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 卵巢癌 (OVCA) 是女性癌症死亡的主要原因.
- 尽管在其他癌症中已知其瘤抑制功能,但在OVCA中Mitotic Arrest Deficient 2 Like 2 (MAD2L2) 的作用尚不清楚.
研究的目的:
- 研究MAD2L2在卵巢癌中的表达,生物功能和预后意义.
- 探索MAD2L2对OVCA细胞增殖,迁移,新陈代谢和免疫细胞相互作用的影响.
主要方法:
- 生物信息学对基因组改变和mRNA表达的分析.
- 考克斯回归分析用于预后意义.
- 在体外细胞实验中评估功能角色.
- 基因本体学和KEGG通路分析用于功能丰富.
主要成果:
- MAD2L2表现出基因组变化 (放大,删除) 并在OVCA中过度表达,与生存率降低有关,特别是在第四级瘤中.
- MAD2L2涉及器官核糖体局部化,NADH脱酶活性,线粒体翻译,瘤代谢和细胞死亡.
- MAD2L2表达与免疫细胞透相关,并促进OVCA细胞的增殖和迁移,同时通过mTOR信号抑制铁亡.
结论:
- MAD2L2是卵巢瘤进展的新型调节剂.
- 它的过度表达会影响OVCA细胞的行为,新陈代谢和免疫微环境.
- MAD2L2为卵巢癌治疗提供了潜在的治疗标.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
02:30Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K